---
title: 'Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL:
  Final Comparative Analysis of ALPINE'
date: '2024-09-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39316666/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240925194758&v=2.18.0.post9+e462414
source: Blood
description: 'ALPINE (NCT03734016) established the superiority of zanubrutinib over
  ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and
  small lymphocytic lymphoma (R/R CLL/SLL); here we present data from the final comparative
  analysis with extended follow-up. Overall, 652 patients received zanubrutinib (n=327)
  or ibrutinib (n=325). At an overall median follow-up of 42.5 months, progression-free
  survival benefit with zanubrutinib vs ibrutinib was sustained (HR: 0.68 [95% ...'
disable_comments: true
---
ALPINE (NCT03734016) established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL); here we present data from the final comparative analysis with extended follow-up. Overall, 652 patients received zanubrutinib (n=327) or ibrutinib (n=325). At an overall median follow-up of 42.5 months, progression-free survival benefit with zanubrutinib vs ibrutinib was sustained (HR: 0.68 [95% ...